A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer-Reference-Cited by-同舟云学术

A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer

Published:2022-01 Issue:1 Volume:22 Page:67-77
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

LoRusso Patricia,Hamilton Erika,Ma Cynthia^ORCID,Vidula Neelima,Bagley Rebecca G.,Troy Steven,Annett Miriam^ORCID,Yu Ziyang,Conlan Maureen G.^ORCID,Weise Amy

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Cancer statistics;Siegel;CA Cancer J Clin,2019

2. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state;Kohler;J Natl Cancer Inst,2015

3. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer;Huang;J Clin Pathol,2005

4. Expression of androgen receptors in primary breast cancer;Park;Ann Oncol Off J Eur Soc Med Oncol,2010

5. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study;Collins;Mod Pathol an Off J United States Can Acad Pathol Inc,2011

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myopericarditis Following Use of Selective Androgen Receptor Modifier “RAD-140”;JACC: Case Reports;2024-08

2. Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use;JCEM Case Reports;2024-07-24

3. Advances in SARMs anti‐doping analysis;Drug Testing and Analysis;2024-05-06

4. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial;The Lancet Oncology;2024-03

5. Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer;International Journal of Molecular Sciences;2024-02-02